成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Lenvatinib Mesylate

別名: E7080 mesylate 中文名稱：甲磺酸樂伐替尼

Lenvatinib Mesylate是一種合成、具有口服活性的 tyrosine kinase 的抑制劑，可抑制血管內(nèi)皮生長(zhǎng)因子受體(VEGFR1-3)，成纖維細(xì)胞生長(zhǎng)因子受體(FGFR1-4)，血小板衍生生長(zhǎng)因子受體(PDGFRα)，干細(xì)胞因子受體(Kit (c-Kit))，并在轉(zhuǎn)染過程中重新排列(RET (c-RET))。甲磺酸來(lái)伐替尼具有潛在的抗腫瘤活性。

Lenvatinib Mesylate Chemical Structure

Lenvatinib Mesylate Chemical Structure

CAS: 857890-39-2

規(guī)格 價(jià)格 庫(kù)存 購(gòu)買數(shù)量
10mM (1mL in DMSO) 810.81 現(xiàn)貨
25mg 794.79 現(xiàn)貨
100mg 1793.61 現(xiàn)貨
1g 9582.54 現(xiàn)貨
更大包裝 有超大折扣

400-668-6834

info@selleck.cn
免費(fèi)分裝
免費(fèi)預(yù)溶

Lenvatinib Mesylate相關(guān)產(chǎn)品

相關(guān)信號(hào)通路圖

VEGFR Signaling Pathways

VEGFR信號(hào)通路圖

細(xì)胞實(shí)驗(yàn)數(shù)據(jù)示例

細(xì)胞系 實(shí)驗(yàn)類型 給藥濃度 孵育時(shí)間 活性描述 文獻(xiàn)信息
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells 29435139
Rh18 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells 29435139
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells 29435139
Rh18 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells 29435139
點(diǎn)擊查看更多細(xì)胞系數(shù)據(jù)

生物活性

產(chǎn)品描述 Lenvatinib Mesylate是一種合成、具有口服活性的 tyrosine kinase 的抑制劑，可抑制血管內(nèi)皮生長(zhǎng)因子受體(VEGFR1-3)，成纖維細(xì)胞生長(zhǎng)因子受體(FGFR1-4)，血小板衍生生長(zhǎng)因子受體(PDGFRα)，干細(xì)胞因子受體(Kit (c-Kit))，并在轉(zhuǎn)染過程中重新排列(RET (c-RET))。甲磺酸來(lái)伐替尼具有潛在的抗腫瘤活性。
靶點(diǎn)
c-RET [2] VEGFR2 [1]
(Cell-free assay)		 VEGFR3 [1]
(Cell-free assay)		 VEGFR1 [1]
(Cell-free assay)		 PDGFRβ [1]
(Cell-free assay)		 點(diǎn)擊更多
4.0 nM 5.2 nM 22 nM 39 nM
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06161558 Not yet recruiting
Neoplasms
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
 May 15 2024 Phase 1
NCT05846724 Not yet recruiting
Kaposi Sarcoma|Classic Kaposi Sarcoma|Refractory Kaposi Sarcoma
Fondazione IRCCS Ca'' Granda Ospedale Maggiore Policlinico
 February 1 2024 Phase 2
NCT05903833 Not yet recruiting
Recurrent Vulvar Cancer|Persistent Vulvar Cancer|Metastatic Vulva Cancer|Locally Advanced Vulvar Cancer
AGO Research GmbH
 January 1 2024 Phase 2
NCT05901194 Not yet recruiting
Hepatocellular Carcinoma Non-resectable
Assistance Publique - H?pitaux de Paris|Laboratoire EISAI
 June 2023 Phase 1|Phase 2

化學(xué)信息&溶解度

分子量 522.96 分子式

C21H19ClN4O4.CH4O3S
CAS號(hào) 857890-39-2 SDF --
Smiles COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl.CS(=O)(=O)O
儲(chǔ)存條件(自收到貨起) 3年 -20°C 粉狀

體外溶解度
批次：

DMSO : 30 mg/mL ( (57.36 mM) ；DMSO吸濕會(huì)降低化合物溶解度，請(qǐng)使用新開封DMSO)

Water : Insoluble

Ethanol : Insoluble

摩爾濃度計(jì)算器

體內(nèi)溶解度
批次：

現(xiàn)配現(xiàn)用，請(qǐng)按從左到右的順序依次添加，澄清后再加入下一溶劑

 動(dòng)物體內(nèi)配方計(jì)算器

實(shí)驗(yàn)計(jì)算

摩爾濃度計(jì)算器

質(zhì)量 濃度 體積 分子量

動(dòng)物體內(nèi)配方計(jì)算器（澄清溶液）

第一步：請(qǐng)輸入基本實(shí)驗(yàn)信息（考慮到實(shí)驗(yàn)過程中的損耗，建議多配一只動(dòng)物的藥量）

mg/kg g μL 只

第二步：請(qǐng)輸入動(dòng)物體內(nèi)配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請(qǐng)聯(lián)系Selleck為您提供正確的澄清溶液配方）

% DMSO % % Tween 80 % ddH2O
%DMSO %

計(jì)算結(jié)果：

工作液濃度： mg/ml；

DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過該批次藥物DMSO溶解度，請(qǐng)先聯(lián)系Selleck）；

體內(nèi)配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH2O，混勻澄清。

體內(nèi)配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。

注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進(jìn)行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。

技術(shù)支持

在訂購(gòu)、運(yùn)輸、儲(chǔ)存和使用我們的產(chǎn)品的任何階段，您遇到的任何問題，均可以通過撥打我們的熱線電話400-668-6834，或者技術(shù)支持郵箱tech@selleck.cn，直接聯(lián)系到我們。我們會(huì)在24小時(shí)內(nèi)盡快聯(lián)系您。

操作手冊(cè)

如果有其他問題，請(qǐng)給我們留言。

* 必填項(xiàng)

請(qǐng)輸入您的姓名
請(qǐng)輸入您的郵箱地址 請(qǐng)輸入一個(gè)有效的郵箱地址
請(qǐng)寫點(diǎn)東西給我們
Tags: buy Lenvatinib Mesylate | Lenvatinib Mesylate supplier | purchase Lenvatinib Mesylate | Lenvatinib Mesylate cost | Lenvatinib Mesylate manufacturer | order Lenvatinib Mesylate | Lenvatinib Mesylate distributor
在線咨詢
聯(lián)系我們